The posts here offer some general information on the fundamental techniques used in our work and their applications. This is one of the main groups of posts. We cover therapeutic antibody structure, biosimilars and their comparability analysis, fragment screening, and fragment-based drug discovery, including methods like weak-affinity chromatography (WAC) and crystallographic fragment screening, as well as room-temperature crystallography at synchrotrons, among others.
We discuss the advantages of using X-ray crystallography and cryo-EM in 3D epitope mapping. We show that these methods can reveal conformational dynamics and allosteric effects within the antibody-antigen complex.
We highlight a study conducted by the AstraZeneca team on synchrotron X-ray crystallography in drug discovery (Käck & Sjögren, 2024).
Technical developments have made crystallographic fragment screening the most effective method for screening fragment libraries. Here, we provide a brief overview of the method and its requirements.
Macrocyclic peptide drug structures (often 4 to 24 amino acids) fall between small-molecule drugs and biologics (such as monoclonal antibodies). We discuss the unique features of these structures.
We discuss the the early drug discovery services market and highlight the integrated drug discovery CRO services provided by SARomics Biostructures.
In the this article we discuss evidence that shows that NMR spectroscopy is far superior to other established methods for biosimilar’s higher order structure analysis.
In this article, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
After many years of cryo-crystallography dominance, room-temperature X-ray crystallography using synchrotron radiation has returned. We discuss the application of room-temperature X-ray crystallography in drug design.
In this post, we discuss therapeutic antibodies and biosimilars and the need for biosimilar comparability analysis and characterization, with a focus on methods for assessing structural comparability.
In this third post on structural biology and structure-based drug design we discuss methods and benefits of fragment-based lead discovery